Researchers at the University of Pittsburgh gave transplant recipients certain immune cells from their organ donors. It ...

As shares of Replimune Group  (REPL) hit an all-time low on Monday of $1.50 following the US FDA's rejection of its lead ...

The pharma industry “own Congress, they own the media,” Health Secretary Robert F. Kennedy, Jr. told lawmakers by way of ...

For the second time, the U.S. Food and Drug Administration has refused to approve Replimune Group’s experimental skin cancer ...

Replimune’s CEO Sushil Patel has already warned that the biotech will need to cut staff and substantially scale back its U.S. manufacturing operations.

Philip Astley-Sparke, executive chairman and co-founder at Replimune, joins ‘Squawk on the Street’ to discuss the company's ...

With our free press under threat and federal funding for public media gone, your support matters more than ever. Help keep the LAist newsroom strong, become a monthly member or increase your support ...

Add Yahoo as a preferred source to see more of our stories on Google. Eledon's kidney transplant rejection drug Eledon Pharmaceuticals’ lead asset, tegoprubart, is going to late-stage trials in kidney ...

What just happened? The dream of a cure for type 1 diabetes may have taken a step closer after a man with the disease received a transplant of genetically altered pancreatic cells that allowed his ...

Do you take any medications? Nearly half of all Americans take prescription drugs (Demography, Oct. 1, 2023). Make that 85 ...